09:03 AM EST, 02/26/2025 (MT Newswires) -- Zymeworks ( ZYME ) said Wednesday that it has achieved a $14 million cash research clinical milestone from GSK (GSK).

The companies signed a platform technology transfer and license agreement in 2016 to research, develop, and commercialize up to six bispecific antibodies generated using Zymeworks' ( ZYME ) Azymetric platform, Zymeworks ( ZYME ) said, adding that it is eligible to receive up to $1.1 billion in milestone payments.

Zymeworks' ( ZYME ) stock was up 3% in recent Wednesday premarket activity, while GSK's shares were down 1.3%.